In a public health clinic on the outskirts of Kampala, Uganda, a nurse hands a small white paper bag to a woman in her fifties. Inside are thirty tablets of levothyroxine, enough for the month ahead. The woman has been coming to this clinic for nearly two years, and she knows the routine: arrive before the queue forms, wait for the nurse to check her file, collect the tablets, and return next month. She does not receive a paper prescription to take to an outside pharmacy, because in practice, those prescriptions often take weeks to fill, if they are filled at all.

This scene repeats itself across many low- and middle-income settings, where the gap between what evidence recommends and what clinicians actually do is visible in every waiting room. The clinic dispenses thyroid tablets directly, a practice that ensures some continuity of care, while the formal prescription system, designed for a different context, fails patients who cannot afford the time, travel, or cost of chasing a paper script. The tension is not a minor administrative annoyance. It shapes who gets treated, who falls through the cracks, and how much the system ultimately pays for acute care that could have been prevented.

The Clinic Dispenses, the Pharmacy Waits

At the Kampala clinic, dispensing thyroid medication directly to patients is a matter of survival. The clinic buys the tablets in bulk, stores them in a locked cabinet, and hands them out monthly. Patients do not need to present a prescription at an outside pharmacy, because the clinic itself acts as the pharmacy. This arrangement has evolved informally, driven by the simple observation that patients who leave with tablets in hand are more likely to continue treatment than those who leave with a piece of paper.

Paper prescriptions, by contrast, sit unfilled for weeks. A patient might receive a script for levothyroxine, but the pharmacy may be out of stock, or the pharmacist may require the exact refill date and dosage, which the patient cannot recall. The cost of travel to the pharmacy, often several hours by bus, can exceed the cost of the medication itself. Some patients simply give up, returning to the clinic only when symptoms worsen. Others hoard tablets when they can get them, rationing doses to stretch supply, which is dangerous for a hormone replacement therapy where consistency matters.

The system rewards walk-ins over formal scripts. A patient who shows up at the clinic without an appointment can often get a refill, because the clinician knows the patient and can see the treatment history. A patient who presents a paper prescription at a distant pharmacy is just another customer, and the pharmacy has no incentive to prioritize that script over others. The result is a two-tier system: those who live near the clinic or can afford frequent visits get steady supply, while those who rely on the formal prescription pathway face delays that can last weeks.

The waiting room at the Kampala clinic is a daily reminder of this imbalance. Some patients arrive with empty pill bottles, hoping the nurse will recognize them. Others bring crumpled paper scripts, yellowed with age, that they have been carrying for weeks. The nurse does her best, but the system is not designed to catch everyone. The tension is not just about logistics; it is about who gets to be treated as a person rather than a file number.

Why Paper Prescriptions Fail in Low-Resource Settings

Paper prescriptions fail for reasons that are well documented in global health literature. They get lost, damaged, or delayed. In humid climates, paper disintegrates. In busy households, scripts are misplaced. Pharmacies demand exact refill dates, and if the patient cannot produce the original script or the dates do not match, the pharmacist may refuse to dispense. The patient then faces a choice: travel back to the clinic to get a new script, or go without medication.

Stock-outs at pharmacies compound the problem. Even when a patient does present a valid script, the pharmacy may be out of the specific dosage. In low-resource settings, supply chains are fragile, and thyroid medications, which are relatively cheap but not always prioritized, can be unavailable for weeks. This forces patients to ration their existing supply, taking half a tablet every other day, which destabilizes hormone levels and can trigger symptoms.

Informal networks fill the gaps unevenly. A patient might ask a relative who lives near the clinic to pick up a refill, or a community health worker might carry a bag of tablets on home visits. These workarounds help some patients but not all, and they depend on social connections that not everyone has. The result is a patchwork of care that leaves many patients untreated for weeks at a time.

Evidence Says Continuous Supply Beats Perfect Adherence

Evidence from endocrinology and public health strongly supports the idea that continuous supply of thyroid hormone is more important than perfect adherence to a prescribed schedule. For hypothyroidism, the goal is to maintain stable hormone levels, and interruptions in supply cause levels to fluctuate, leading to symptoms such as fatigue, weight gain, and cognitive slowing. In severe cases, prolonged gaps can precipitate myxedema coma, a life-threatening emergency.

Studies in high-income settings have shown that continuous therapy reduces hospital readmissions for thyroid-related complications. A patient who consistently takes levothyroxine is less likely to end up in the emergency department with uncontrolled hypothyroidism. The same logic applies in low-resource settings, where the cost of an emergency visit is borne by the patient and the system alike.

Adherence metrics, which are often used to evaluate treatment success, miss supply chain failures entirely. When a patient misses a refill, the electronic record may show a gap in medication possession, but it does not distinguish between a patient who chose not to take the medication and a patient who could not obtain it. This conflation is a serious flaw in how we measure the quality of care.

Clinic dispensing, by contrast, shows better outcomes in practice. When the clinic hands out tablets directly, the patient does not have to navigate a separate pharmacy, and the clinician can adjust the dose at the same visit. Data from low-income countries, though limited, suggest that programs that integrate dispensing into primary care visits achieve higher rates of treatment continuation than those that rely on external prescriptions.

What Clinicians Do Versus What Guidelines Recommend

Clinical guidelines for hypothyroidism typically recommend regular monitoring of thyroid function tests and adjustment of the levothyroxine dose as needed. They do not explicitly recommend that clinics dispense the medication themselves, because in most high-income settings, the pharmacy is a reliable partner. In low-resource settings, however, clinicians adapt to local realities, and dispensing becomes a pragmatic workaround.

Paper prescriptions remain a legal requirement in many countries, even when they are not practically useful. A clinician may write a script because the law demands it, but then also hand the patient a bag of tablets from the clinic's own supply. This dual-track approach, which is common, is a testament to the gap between regulation and reality.

Digital systems offer a way around some of these problems, but they are not universally available. Where electronic prescribing exists, it can reduce errors and delays, but it requires infrastructure, training, and reliable electricity, all of which are scarce in many low-resource settings. As one clinician in Kampala put it, "We have the tablets, we have the patients, and we have the knowledge. What we do not have is a piece of paper that works."

Trust drives patients to clinic refills. A patient who has been coming to the same clinic for years trusts the nurse who knows their history. That trust is a clinical asset, and it is one reason why clinic dispensing, despite its informality, is often more effective than the formal prescription pathway.

The Cost of Waiting: Clinical and Economic Harm

Weeks of untreated hypothyroidism are not benign. Patients experience worsening fatigue, depression, and cognitive impairment, which can make it hard to work or care for family. The physical effects include weight gain, constipation, and muscle aches, and in some cases, the cardiovascular system is strained by the hormone imbalance. For a patient with pre-existing heart disease, the risk is even higher.

The economic harm extends beyond the individual. Missed work days and lost productivity affect household income, and family members often have to step in to provide care. The system pays more for acute care than for prevention: a single emergency visit for myxedema coma can cost more than a year of levothyroxine. Yet the incentives are misaligned, because the cost of the emergency is borne by the hospital, while the cost of the medication is borne by the patient.

Emergency visits spike after gaps in supply. A patient who has been off medication for several weeks may present with confusion or shortness of breath, and the hospital must stabilize them with intravenous hormones and intensive monitoring. These are preventable admissions, but they happen every day in low-resource settings.

The cumulative cost is enormous, both in human suffering and in financial terms. A study from a neighboring country estimated that improving access to continuous thyroid medication could reduce emergency admissions by a third, saving the health system more than it would cost to provide the medication. The evidence is there, but the policy has not caught up.

A Simple Fix: Dispense at the Point of Care

The most straightforward solution is to make clinic dispensing the default, not the exception. When the clinic provides the medication at the same visit, the patient does not have to make a separate trip, and the clinician can ensure the dose is correct. This reduces abandonment and improves adherence, because the patient leaves with the tablets in hand.

Electronic records can track refills automatically, alerting clinicians when a patient is overdue. In clinics where such systems exist, they have been shown to reduce gaps in treatment. But even without sophisticated technology, a simple paper log can serve the same purpose, as long as someone is responsible for updating it.

Pilot programs in urban clinics across East Africa have shown that dispensing thyroid medication at the point of care is feasible and acceptable to patients. Staff training is minimal, and the cost of the medication is often lower than the cost of the logistics involved in the prescription pathway. The main barrier is policy: many governments require prescriptions to be filled by licensed pharmacies, even when the clinic is better equipped to do so.

Policy change could enable this everywhere, but it requires a shift in mindset. Regulators need to recognize that in low-resource settings, the clinic may be the most reliable pharmacy. As one health economist noted, "The system was designed for a world that does not exist here. We need to design for the world we live in."

For Patients and Providers: Practical Steps

For patients, the first step is to ask the clinic about direct dispensing options. Many clinics already have a supply of thyroid tablets, even if they do not advertise it. Bringing old pill bottles to appointments helps the clinician verify the dose and the refill date, and it reduces the risk of errors.

Mobile reminders for refill dates can help patients stay on schedule, especially in areas where phone ownership is common. Simple text messages have been shown to improve adherence in other chronic conditions, and the same approach can work for thyroid medication. Providers should document supply gaps, not just adherence, so that the system can identify and address structural barriers.

Advocacy for prescription digitalization is important, but it is not a short-term fix. In the meantime, clinicians can work within the existing system to ensure that patients who need thyroid medication get it, whether that means dispensing directly or helping patients navigate the pharmacy pathway. The goal is to avoid gaps, because every gap is a step toward a preventable emergency.

None of these steps is a silver bullet, and the trade-offs are real. Clinic dispensing may reduce the role of pharmacies, which could have unintended consequences for the pharmaceutical sector. But the evidence suggests that the benefits outweigh the risks, and that a pragmatic approach can improve outcomes for the patients who need it most.